RxDoctor Payments DataLook up a doctor →

Gurusher Panjrath, MD

Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1437325883

Payments from drug & device makers

$841,779in general payments, 2019–2025

Across 569 payments — averaging $1479.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$270K
  • Cvrx, Inc.$247K
  • Pfizer$137K
  • Ionis Pharmaceuticals, Inc.$51K
  • Alnylam Pharmaceuticals Inc.$47K
  • United Therapeutics Corporation$26K
  • plus $62K from 23 others
$751in research payments, 2019–2025

Across 1 payment — averaging $750.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$751

What the payments were for

  • Consulting fees$192,05145%
  • Speaking & faculty fees$166,06539%
  • Travel & lodging$40,43810%
  • Food & beverage$27,0106%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$131,701
Medicare patients
323
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis42$1,467,581
EntrestoSacubitril/Valsartan319$402,705
JardianceEmpagliflozin274$314,784
EliquisApixaban78$84,047
FarxigaDapagliflozin Propanediol54$40,534
VerquvoVericiguat16$30,508
OzempicSemaglutide23$22,363
TrulicityDulaglutide16$14,433
XareltoRivaroxaban20$13,280
CorlanorIvabradine Hcl17$10,760
Metoprolol Succinate237$3,614
Bumetanide64$2,511
Spironolactone275$2,342
Eplerenone20$1,754
Midodrine Hcl16$1,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$137,271$1,551,628120 claims
NovartisEntresto$163$402,705319 claims
AstraZenecaFarxiga$109$40,53454 claims
MerckVerquvo$270,195$30,50816 claims
Novo NordiskOzempic$34$22,36323 claims
AmgenCorlanor$335$10,76017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →